Content Type: Article

  • Lawmakers Revisit Tax Treatment of Carried Interest

    Lawmakers Revisit Tax Treatment of Carried Interest

    CLIENT ALERT / US POLICY

    Lawmakers Revisit Tax Treatment of Carried Interest

    February 21, 2025

    Read time: 5 min

    Key takeaways
    Overview

    The tax treatment of carried interest has long been a subject of political debate. Since 2007, almost annually, the taxation of carried interest has found its way into either proposed legislation or presidential budget proposals. Most recently, on February 6, 2025, US President Donald Trump had discussions with Republican leadership while Democratic leadership reintroduced legislative proposals to treat carried interest as ordinary income.

    In depth

    Overview of Carried Interest

    Private investment fund sponsors typically receive management fees (based on a specified percentage of the fund’s capital commitments) and carried interest. Frequently referred to as a “loophole,” carried interest is a contractual right that qualifies as a “profits interest” for tax purposes, entitling the sponsor to a share of the gain recognized by an investment fund. Like any other partner, the character of the income or gain allocated to the sponsor with respect to carried interest is determined based on the character of the income or gain recognized by the fund. If the sponsor’s carried interest is attributable to qualified dividend income or, subject to the limitations imposed under Section 1061 of the Internal Revenue Code, long-term capital gain recognized by the fund, the sponsor is eligible for favorable federal income tax rates (generally at a 23.8% federal income tax rate).

    Section 1061 and the 2021 Treasury Regulations

    Enacted in 2017 as part of the Tax Cuts and Jobs Act, Section 1061 recharacterizes certain gain that would otherwise qualify as long-term capital gain with respect to “applicable partnership interests” as short-term capital gain. An applicable partnership interest is any interest in a partnership that, directly or indirectly, is transferred to – or is held by – a taxpayer in connection with the performance of substantial services by that taxpayer, or any other related person, in any applicable trade or business. Under Section 1061, a three-year holding period (instead of the typical one-year holding period) generally is required for a carried interest holder to qualify for long-term capital gains treatment.

    Prior Carried Interest Proposals

    Prior to the enactment of Section 1061, several carried interest recharacterization bills and other similar legislative proposals were considered by US Congress. Beginning in 2007, many bills proposed to tax all or a portion of income earned by fund sponsors from carried interest as ordinary income. One set of proposals would have applied solely to funds engaged in investment or real estate activities while a broader set of these proposals would have applied to carried interest from any fund, regardless of the fund’s activities.

    Various proposals sought to treat certain net income derived from, and gain on the disposition of, an “investment services partnership interest” as ordinary income. This would have subjected the income and gain to a higher tax rate and self-employment taxes. These bills generally defined an “investment services partnership interest” as a partnership interest held by any person in connection with the conduct of a trade or business that involves certain investment activities, which would include most fund sponsors.

    Since the enactment of Section 1061, Congress has continued to consider the federal income tax treatment of carried interest. Notably, as part of the deliberations over what became the Inflation Reduction Act of 2022, Congress considered further limiting long-term capital gain eligibility for carried interest by, among other things, increasing the required holding period from three to five years.

    Current Carried Interest Legislation Proposals

    On February 6, 2025, President Trump met with Republican leadership and discussed including the elimination of preferential tax treatment for carried interest in a list of priorities he wants to accomplish in this year’s tax bill. While President Trump previously called for ending capital gains eligibility for carried interest in his 2016 campaign tax reform, the Tax Cuts and Jobs Act of 2017 only tightened eligibility requirements by enacting Section 1061.

    On the same day President Trump discussed ending the carried interest preferential treatment, Democratic leadership proposed new bills that would treat carried interest as compensation (taxed at ordinary income tax rates and subject to self-employment taxes), eliminate the preferential tax treatment of qualified dividends, and eliminate the exclusion for gain from the sale of qualified small business stock, in each case, to the extent realized with respect to an investment services partnership interest.

    The Trump administration’s policy on carried interest has not yet been fully defined and current bills on the tax treatment of carried interest are in the beginning stages of the legislative process, so it remains to be seen whether carried interest holders’ eligibility for preferential tax rates will be further curtailed or eliminated altogether.

    McDermott’s tax and investment funds teams have extensive experience helping investment fund sponsors navigate the complexities of carried interest taxation. If you have questions or need advice, please contact your primary McDermott lawyer, the authors of this article, or a member of our investment funds team.

    Authors

    Kevin Hall

    Partner

    Miami

    Alejandro Ruiz

    Partner

    San Francisco

    Wondha Cadet

    Associate

    Chicago

    More insights

  • Preparing for 2025: Key Trends in FDA Guidance Agendas

    Preparing for 2025: Key Trends in FDA Guidance Agendas

    ARTICLE / CLIENT ALERT

    Preparing for 2025: Key Trends in FDA Guidance Agendas

    February 21, 2025

    Read time: 6 min

    Key takeaways
    Overview

    In January 2025, various US Food and Drug Administration (FDA) centers and offices published their guidance agendas for the 2025 calendar year (CY). These agendas provide valuable insights into FDA’s regulatory priorities, suggesting where industry stakeholders might encounter new oversight-related opportunities and challenges in the coming year. These guidance agendas are not set in stone, however. Because all were published in the last days of the Biden administration, the emerging Trump administration FDA will likely direct units to publish updated versions reflecting changed priorities in the near future.

    Five of FDA’s centers and offices published their CY 2025 guidance agendas in early to mid-January: the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Oncology Center of Excellence (OCE), the Office of the Chief Scientist (OCS), and the Office of the Chief Medical Officer (OCMO). The centers’ agendas anticipate more than 170 total guidance documents that will cover a wide range of impactful topics, including compounding, cell and gene therapy products, and clinical trial operations.

    In depth

    Despite the impressive breadth of topics covered by the various guidance agendas, some overarching trends and priorities are apparent. For example, guidance related to clinical trials and study design has been slated to receive a significant amount of attention in CY 2025, with CDER, OCE, and OCMO all prioritizing drafts related to these topics. Examples include the following:

    Guidance Type Issuing Center
    Master Protocols for Drug and Biological Product Development Revised Draft CDER
    Informative Bayesian Methods in Pediatric Clinical Trials Draft Guidance CDER
    Considerations for the Inclusion of Older Adults in Clinical Trials Draft Guidance CDER
    Clinical Pharmacogenomics: Evaluation, Study Design, and Analysis Draft Guidance CDER
    Approaches to Assessment of Overall Survival in Oncology Clinical Trials Draft Guidance OCE
    Institutional Review Board Waiver or Alteration of Informed Consent for Minimal Risk Research Draft Guidance OCMO

    Biosimilars and biologics have also been slated for attention in CY 2025. CDER and CBER have identified opportunities to draft and finalize guidance on subtopics such as the following:

    Guidance Type Issuing Center
    Pediatric Study Plans for Biosimilar Products Draft Guidance CDER
    Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Revised Draft CDER
    Considerations for the Use of Human- and Animal-Derived Materials in Cell and Gene Therapy Final Guidance CBER
    Clinical Pharmacogenomics: Evaluation, Study Design, and Analysis Draft Guidance CDER
    Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products Final Guidance CBER

    The omission of certain topics from the units’ guidance agendas is of equal note. New guidance related to artificial intelligence (AI) standards did not appear on any January 2025 agendas. However, the Center of Devices and Radiological Health’s agenda, published in October 2024 (and discussed in this On the Subject) included two AI-related guidances. Additionally, the Biden administration issued two much-anticipated draft guidance documents in January 2025 addressing the use of AI in drugs and devices. McDermott will closely monitor this area as the Trump administration decides whether to adopt a novel approach to AI governance.

    CDER

    CDER’s CY 2025 guidance agenda spans 15 topic areas, including labeling, pharmaceutical quality, current good manufacturing practices, compounding, and generics.

    The agenda places particular emphasis on providing industry stakeholders with information and resources related to abbreviated new drug applications (ANDAs) for generic drug products. Planned ANDA-related guidance will cover topics such as submission content and formatting, general considerations for ANDAs in the pediatric exclusivity context, and frequently asked questions (FAQs) on refuse-to-receive standards.

    CDER also plans to develop several guidance documents discussing allowable compounding practices under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

    CBER

    The CBER CY 2025 guidance agenda focuses on two main categories: therapeutic products, and blood and blood components. Within the therapeutics category, CBER expects to draft and finalize a suite of guidances helping stakeholders navigate various aspects of cell and gene therapy product regulation. Forecasted publications include FAQs related to cell and gene therapy products, and documents covering accelerated approval of gene therapy products for rare diseases.

    OCE

    Although OCE does not typically publish an independent regulatory agenda, it opted to do so for CY 2025. Its agenda lists several highly important guidances for stakeholders in the oncology space, including “Approaches to Assessment of Overall Survival in Oncology Clinical Trials” and “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.”

    OCS

    The OCS CY 2025 guidance agenda is centered on two key topics: cosmetic products and ethical standards for FDA advisory committees. The guidance documents related to cosmetic products will address mandatory recalls and records access and are being developed in concert with the FDA Office of Inspections and Investigations.

    OCMO

    The OCMO CY 2025 guidance agenda touches on subjects related to clinical trials, combination products, medical products, and rare diseases. OCMO expects to issue final guidance titled “How to Prepare a Pre-Request for Designation (Pre-RFD)” as well as several new draft guidances, including an overview of the orphan drug designation program.

    In addition to inviting general comments on the substantive topic areas covered by each of the proposed guidance documents, CDER, CBER, OCE, OCS, and OCMO request stakeholder comments on how the guidance documents should be prioritized internally.

    * * * * * *

    The McDermott Difference

    McDermott will continue to monitor any changes the Trump administration makes to the centers’ and offices’ guidance agendas. If you are interested in submitting comments to any of the above centers or have questions about how the CY 2025 guidance agendas could impact your business, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Michael W. Ryan

    Partner

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    Henry Fisher

    Associate

    Washington, DC

    More insights

  • Navigating the EPR laws: What acohol beverage producers need to know

    Navigating the EPR laws: What acohol beverage producers need to know

    ARTICLE

    Navigating the EPR laws: What acohol beverage producers need to know

    Feb 21, 2025

    Read time: 5 min

    Key takeaways
    Overview

    Extended producer responsibility (EPR) laws are relatively new – the first were signed into law in 2021 and 2022 – and are aimed at encouraging producers to package goods in a more environmentally conscientious manner and providing much needed revenue for in-state recyclers overwhelmed by the incoming volumes of recyclable material. In essence, EPR laws require producers whose products reach in-state consumers to register with a producer responsibility organization (PRO) or stewardship organization (SO), report the amount of material that enters the state, and pay fees for that material.

    As detailed in this blog post, how and if these new laws apply to alcohol beverage suppliers is nuanced given both the developing nature of EPR laws as well as the interplay with preexisting container deposit or bottle bill laws.

    Who and What Is Covered by the New EPR Laws?

    As of the writing of this article, five states have passed EPR laws and 10 others have introduced bills during their most recent legislative sessions, including Connecticut, Hawaii, Nebraska, and New York. EPR programs are still evolving as the various regulatory processes continue; however, once passed by a state, the new rules typically require the state to designate a PRO/SO to administer the producer requirements and aid producers and state agencies with the necessary reporting and payment requirements. For those states that have passed EPR laws, the nonprofit organization Circular Action Alliance is the PRO/SO that has been selected to oversee the process.

    Each EPR law has its own definition of “producer” (i.e., those required to report) and of “covered material” (i.e., the materials that must be reported). There are several specifics within each state but, generally, the producer is the entity who actually produces the subject goods or the owner of the brand that is contracting to have the item produced. Speaking broadly, the covered material contemplated by these laws includes the cardboard boxes and glass or aluminum containers that protect and contain the items purchased from retailers. In this regard, EPR laws apply to alcoholic beverages, non-alcoholic beverages, and nearly all other types of consumer goods.

    However, exemptions exist for small producers and certain materials. The specifics as to when a producer is exempt from registering and making EPR payments vary by state but, in many instances, those producers shipping small amounts into a certain state will be exempt. For example, Minnesota exempts producers responsible for less than one metric ton of covered material or $2,000,000 in global gross revenue. However, it is important to remember that even if a small producer is, given its status, exempt from registering with a PRO/SO or paying the related EPR fees, it will likely still have reporting requirements to substantiate its claims of being exempt.

    How Do These Laws Apply and Interface with Alcohol Beverage Laws?

    In the world of beverage alcohol, there are numerous laws already in place, many of which have been in force for decades, that are aimed at sustainability and designed to fund and encourage recycling. These are referred to as beverage container deposit/recycling deposit requirements or “bottle bills.” These laws generally require subject beverages to have, listed on their labels, their deposit amount or to otherwise identify the bottle as one that is subject to deposit requirements. They also require a small deposit to be paid by the retailer and/or by the consumer for the purchase of subject beverages, only refunding the deposit to the consumer when the bottle is returned and requiring a reimbursement and handling fee to be paid by distributors and/or manufacturers for the processing/recycling of the containers.

    The exact recycling model, deposit collection, and payment process varies by state. For instance, California does not require the amount of the deposit to be listed on the bottles and requires the distributor and the manufacturer/importer to remit payments, but it does not require the retailer to submit payments, as the retailers are generally acting as the redemption centers for consumers.

    Fortunately, many of the EPR laws specifically exempt items subject to beverage container deposit requirements. However, the interplay between the older beverage container deposit requirements and the newer EPR laws are not always straightforward. For example, in Oregon, “beverage containers” as defined by the recycling deposit regulations are excluded from the definition of “covered products” (i.e., those subject to EPR requirements). But only “water or flavored water; beer or another malt beverage; mineral water, soda water, or a similar carbonated soft drink; kombucha; or hard seltzer” are subject to deposit regulation, not wine or spirits. This means, for a producer that is selling wine, spirits, and malt beverages into Oregon, while they would be able to exclude the weight of the cases for the malt beverages (malt cans/bottles would be exempt), they would still have to calculate the weight of the bottles and cases for the wine and spirits when reporting.

    In short, given the developing nature of these laws, coupled with the nuances of their interplay with other alcohol beverage-specific requirements, there is no one-size-fits-all analysis as to how and when these laws apply to alcohol beverage producers. There are some instances where an alcohol-specific exemption may apply and other states where no such exemption exists. To ensure compliance in this rapidly evolving landscape, each company’s business structure must be examined carefully to determine whether it, or the products it ships, are subject to EPR laws, bottle bills, or both.

    To determine how your business may be impacted by this developing regulatory regime, please contact one of the members of McDermott’s alcohol beverage team.

    Authors

    Alva C. Mather

    Partner

    Washington, DC

    More insights
    Endnotes

  • Trump Administration May Expand Access to IVF Services

    Trump Administration May Expand Access to IVF Services

    CLIENT ALERT / US POLICY

    Trump Administration May Expand Access to IVF Services

    February 20, 2025

    Read time: 2 min

    Key takeaways
    Overview

    On February 18, 2025, US President Donald Trump signed an executive order directing his administration to develop policy recommendations within 90 days to increase access to in vitro fertilization (IVF) services and to reduce the cost of IVF treatments for patients.

    While the executive order has no immediate impact, it represents the Trump administration’s first step in addressing campaign promises to expand coverage for IVF services and limit the out-of-pocket and health insurance costs of IVF treatments. Given bipartisan support for these efforts in US Congress, there is potential for some action at the federal level even though several states already mandate coverage of certain IVF services by health insurance plans. Particular interest will be on how the Trump administration plans to make IVF services more affordable and ensure access to IVF treatment, with the executive order highlighting the Trump administration’s goal of easing “unnecessary statutory or regulatory burdens.”

    Interested parties should continue to monitor developments in this space by the Trump administration and in Congress, with the McDermott health & life sciences team ready to help with navigating federal statutory or regulatory changes impacting the fertility industry.

    In depth
    Authors

    M. Brian Hall ,IV

    Partner

    Washington, DC

    Sarah Kitchell

    Partner

    Boston

    More insights

  • First Circuit Backs But-For Causation Standard in AKS-Based FCA Claims

    First Circuit Backs But-For Causation Standard in AKS-Based FCA Claims

    ARTICLE / CLIENT ALERT

    First Circuit Backs But-For Causation Standard in AKS-Based FCA Claims

    February 20, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On February 18, 2025, in a highly anticipated opinion, the United States Court of Appeals for the First Circuit joined a majority of the circuits in adopting the “but-for” causation standard as the threshold for proving a False Claims Act (FCA) claim based on an Anti-Kickback Statute (AKS) violation. United States v. Regeneron Pharmaceuticals, Inc., No. 23-2086 (1st Cir. Feb. 18, 2025), raises the bar for the government and private relators in AKS-based FCA cases and has important litigation and strategic implications for FCA litigants in the First Circuit and beyond.

    In depth

    In Regeneron, the First Circuit tilted the circuit split even more on whether FCA liability requires a kickback to be the but-for cause of a claim based on the 2010 amendment to the AKS. While the Sixth, Eighth, and now First Circuits all hold that the 2010 amendment’s “resulting from” language requires a but-for showing, the Third Circuit, relying primarily on legislative history, requires only a “causal link” between the alleged kickback and subsequent claim. Regeneron simultaneously resolved an intra-circuit split among the district courts in Massachusetts: United States v. Teva Pharmaceuticals USA, Inc., No. CV 20-11548-NMG, 2023 WL 4565105 (D. Mass. July 14, 2023), and United States v. Regeneron Pharmaceuticals, Inc., No. CV 20-11217-FDS, 2023 WL 6296393 (D. Mass. Sept. 27, 2023), both issued in 2023, reached opposite conclusions as to the meaning of “resulting from” in an FCA case premised on AKS violations. The First Circuit granted interlocutory review of both decisions and heard oral argument in Regeneron in July 2024. The Department of Justice announced its settlement with Teva in October 2024.

    We have been tracking the development of this issue and have briefed it extensively on behalf of our clients before a wide array of courts.

    The Case

    In this case, the government alleged that Regeneron Pharmaceuticals, a drug manufacturer, violated the AKS by knowingly inducing prescriptions of a drug called Eylea by funding copays for certain patients who received the drug. The government argued that when providers submitted Medicare claims for Eylea prescribed to patients who received copay assistance funded by Regeneron, those claims “resulted from” a violation of the AKS regardless of whether the claims would have been made absent Regeneron’s copay assistance. The government maintained that those Medicare claims were accordingly “false or fraudulent” for purposes of the FCA.

    Conversely, Regeneron argued that a claim only “result[s] from” an AKS violation if it includes “items or services” that would not have been paid for by the government absent the AKS violation – in other words, an AKS violation must be a but-for cause of the alleged false claim. Under this view, if a doctor would have submitted a claim for Eylea anyway, then the subsequent Medicare claim cannot have “result[ed] from” Regeneron’s alleged kickbacks.

    The Ruling

    After nearly five years of litigation, the First Circuit sided with Regeneron and held that an AKS-based FCA claim for allegations stemming from the 2010 amendment to the AKS (in other words, a claim based on a “resulting from” theory) requires proof that kickbacks directly changed treatment decisions. The unanimous opinion affirming Judge Saylor’s decision below was issued by a three-judge panel of Circuit Judges Montecalvo, Thompson, and Kayatta. Circuit Judge William J. Kayatta Jr. authored the opinion.

    In Regeneron, the First Circuit was asked to interpret a 2010 amendment to the AKS which provides that a claim “resulting from” a violation of the AKS constitutes a false claim under the FCA. Tuesday’s opinion noted as a threshold matter that this is a matter of first impression in the First Circuit.

    Reviewing the district court’s interpretation of the 2010 amendment’s “resulting from” language de novo, the court first looked at the statutory language at issue. The opinion reasoned that because the phrase “resulting from” has the ordinary meaning of but-for causation, the court may deviate from this “ordinary course” only if the statute in question provides “textual or contextual indications for doing so.” After reviewing the text of the statute, the court found “no language in the 2010 amendment that by itself runs counter to the presumption that ‘resulting from’ calls for proof of but-for causation.”

    After establishing that the text of the amendment itself did not “contraindicate[] a but-for causation standard,” the court next evaluated the government’s contextual arguments. After assessing the legislative purpose of the 2010 amendment, the court nonetheless determined that but-for causation was the proper standard, declining to endorse the government’s view that interpretation of the AKS in the civil context must track the kickback law’s criminal provisions, which do not require proof that reimbursement would not have occurred absent illegal kickbacks. The First Circuit observed that “the criminal provisions of the AKS serve a different purpose than the provisions linking an AKS violation to FCA falsity” and therefore it “makes sense for the 2010 amendment to render a claim false for FCA purposes only when a kickback is the cause of that claim’s submission to the government.”

    The First Circuit also disagreed with the government’s argument that the statutory history counseled against requiring proof of causation to demonstrate falsity under the FCA, instead agreeing with other circuits that have found that “the 2010 amendment did not disturb alternative theories of FCA liability (e.g., false certification)” and stating that “[p]ut simply, claims under the 2010 amendment run on a separate track than do claims under a false-certification theory.”

    Finding “no convincing ‘textual or contextual’ reason to deviate from the default presumption that the phrase ‘resulting from’ as used in the 2010 amendment imposes a but-for causation standard,” the First Circuit held that “to demonstrate falsity under the 2010 amendment, the government must show that an illicit kickback was the but-for cause of a submitted claim.”

    Key Takeaways

    By adopting the “but-for” causation standard in AKS-based FCA claims on a “resulting from” theory, the First Circuit now requires plaintiffs in these cases to show that claims submitted to Medicare would not have occurred but for an illegal kickback.

    While this case delivered a victory to drug manufacturers overall by adopting a pragmatic interpretation of the AKS, which is often used as a basis for FCA claims, the issue of causation in AKS-based FCA claims is far from settled. FCA litigants should be mindful of the binding precedent in their home circuits, and those without controlling caselaw in their circuit should carefully monitor developments in other courts. This issue is ripe for review by the Supreme Court, and eyes will be on SCOTUS to weigh in.

    In short, entities with possible FCA exposure should track this issue carefully, and those with pending cases should review their litigation strategy to account for this development. In particular, and whenever applicable, defendants in FCA actions should raise – or preserve – the argument as to the “but-for” causation standard in “resulting from” cases. We continue to monitor and assess this changing landscape and implications for our clients.

    Authors

    Rebecca Reese

    Associate

    New York – One Vanderbilt Avenue

    Julian L. André

    Partner

    Los Angeles

    Edward B. Diskant

    Partner

    New York – One Vanderbilt Avenue

    Matthew L. Knowles

    Partner

    Boston

    Laura McLane

    Partner

    Boston

    Jennifer B. Routh

    Partner

    Washington, DC

    More insights

  • Survive or Thrive: UK Real Estate Predictions for 2025

    Survive or Thrive: UK Real Estate Predictions for 2025

    ARTICLE / CLIENT ALERT

    Survive or Thrive: UK Real Estate Predictions for 2025

    February 26, 2025

    Read time: 5 min

    Key takeaways
    Overview

    McDermott’s London Real Estate Group co-hosted a roundtable with Knight Frank at our offices in November 2024, titled “Survive or Thrive in 2025”. With market sentiment dominated by this mantra, we wanted to discuss together with key industry figures what their expectations for the year ahead across key asset classes.

    Key takeaways were that the UK real estate market is still fragile, not having completely recovered from 2021, but deals are happening with the amount of dry powder available to be deployed into real estate strategies. With interest rates seemingly peaked and key elections concluded, the appetite to deploy such capital will increase and lead to increased transaction volumes. We then looked at key asset classes to assess whether they will benefit from the general increase in investor confidence.

     

    In depth

    Offices:  2 distinct markets driven by the continued importance of ESG:

    • Prime Offices: To satisfy occupier demand, which is currently outstripping supply, investors and developers face challenges to ensure their buildings meet ESG demands and achieve the valuation premium as prime offices. Future proofing against likely legislative change, occupier demand and technological change is challenging so a premium will be placed on flexible energy efficient and amenity rich buildings.
    • Brown to Green: Older office assets have not historically had the required focus on ESG requirements which have been overlooked in office buildings. With these standards now critical for long-term viability, due to a combination of the gap between seller and buyer pricing aspirations for such assets narrowing and sustained rental growth for “best in class” offices expected in 2025, numerous funds focused on acquiring older office buildings and deploying the substantial capex required to reposition such buildings as prime offices. As the momentum towards return to work continues, these strategies are likely to increase in popularity with the return profile appreciating.

    Operational Real Estate: Remains “hot” however:

    • Data Centres: Energy supplies to data centres is a major factor. Whilst land may be available, the required power supply to these plots is proving an issue (as well as the source of this energy) and the competition for energy from housing (as a key governmental priority), therefore repurposing of existing logistics buildings with certainty of energy supply is likely to increase.
    • Student Accommodation: Possibly an over-saturated market, with reduced student numbers following Covid and affordability issues influencing occupier demand for the premium rental levels sought from PBSA. This may shift investor appetite to other markets where supply is more constrained.
    • Living: Cladding and the implications of the Building Safety Act 2022 remain defining factors for development, the risk/cost of which remains unquantifiable as it is unknown what actions will be taken against developers as no litigation has gone through the court system as yet.
    • Industrial: demand remains high, with October and November 2024 the busiest period in the sector in the last four years. The certainty of the Labour government coming into power in the UK provided some stability for investors.

    Now that we are a month and a half into 2025 with MIPIM around the corner, it seems as though the new mantra of “Strive in 2025” will evolve as the new mantra for 2025 i.e., whilst we are still waiting for those big deals to kick off, with investor confidence increasing, transaction volumes are likely to be well ahead of 2024 and 2023.

    What to Look Out for in the Year Ahead – McDermott’s Predictions for UK Real Estate Trends:

    • A move away from the larger players, as new capital sources are being seen in the market as legitimate potential buyers.
    • Buyers and occupiers are willing to wait and pay more for energy efficient buildings.
    • A drop in interest rates (together with the weakness of the pound) will provide developers and investors with the push needed to invest.
    • Inbound investment from family offices and sovereign wealth likely to increase.
    • Pricing gap between seller and buyer narrowing and triggering interest in older office stock for brown to green strategies.
    • Rental growth continuing for Prime Offices, leading to further yield compression.
    • Data centres to remain a “hot” asset with a continued appetite for logistics (urban logistics through to big box).
    • Return of “best in class” traditional retail (retail parks and shopping centres).
    • A continuation of the merger between real estate and infrastructure as an asset class into “real assets” with investors merging teams and buckets of capital under that banner.
    • The continued march of alternative lenders in the space who will replace conventional lenders who are retrenching from direct lending.

    We are looking forward to MIPIM and discussing these themes with attendees. Please do reach out if you would be interested to meet with the McDermott team, whose knowledge in the real estate sector is pan-European.

    Authors

    Darren Rogers

    Partner

    London – 22 Bishopsgate

    Devina Rana

    Partner

    London – 22 Bishopsgate

    More insights

  • Corporate Transparency Act Update: Reporting Requirements Reinstated With March 21 Deadline

    Corporate Transparency Act Update: Reporting Requirements Reinstated With March 21 Deadline

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Update: Reporting Requirements Reinstated With March 21 Deadline

    February 20, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On Feb. 17, 2025, a judge of the US District Court for the Eastern District of Texas stayed the only remaining nationwide preliminary injunction enjoining enforcement of the Corporate Transparency Act (“CTA”) and staying implementation of the reporting requirements (“Reporting Rule”).[1] Accordingly, the Reporting Rule’s beneficial ownership information report (“BOI Report”) filing obligations are reinstated.[2] The US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) subsequently issued guidance making clear that reporting is now mandatory (rather than voluntary) for reporting companies but extended the BOI Report filing deadlines as follows[3]:

    Entities Created or Registered Before Jan. 1, 2024

    • Reporting companies created or registered in the US prior to Jan. 1, 2024, have until March 21, 2025, to file their initial BOI Reports with FinCEN (these companies would otherwise have been required to report by Jan. 1, 2025).

    Entities Created or Registered in Calendar Year 2024

    • Reporting companies created or registered in the US on or after Jan. 1, 2024, and prior to Dec. 22, 2024, have until March 21, 2025, to file their initial BOI Reports with FinCEN (these companies would otherwise have been required to file a BOI Report 90 days from the date they were first created or registered).
    • Reporting companies created or registered in the US on or after Dec. 22, 2024, and prior to Jan. 1, 2025, will have 90 days from the date they were first created or registered to file their initial BOI Reports with FinCEN.

    Entities Created or Registered in Calendar Year 2025

    • Reporting companies created or registered in the US on or after Jan. 1, 2025, and prior to Feb. 20, 2025, have until March 21, 2025, to file their initial BOI Reports with FinCEN.
    • Reporting companies created or registered in the US on or after Feb. 20, 2025, have 30 days from the date they were first created or registered to file their initial BOI Reports with FinCEN.

    The FinCEN guidance explains that prior to March 21, 2025, “FinCEN will assess its options to further modify deadlines, while prioritizing reporting for those entities that pose the most significant national security risks.” In addition, FinCEN “intends to initiate a process this year to revise the BOI reporting rule to reduce [the] burden for lower-risk entities, including many U.S. small businesses.” Accordingly, reporting companies may see additional regulatory relief in the near term.

    Clients who deferred filing BOI Reports while the nationwide preliminary injunctions and stays of enforcement were in place should prepare their BOI Reports and timely file them by the appropriate deadlines. Clients that have recently created or registered entities in the US should, contemporaneously with the creation/registration, analyze whether such entities are reporting companies under the Reporting Rule and timely file BOI Reports. Also, please note that any reporting company that was in existence on or after Jan. 1, 2024, is required to file a BOI Report, unless otherwise exempt, even if dissolved prior to its BOI Report filing deadline (as set forth above).[4]

    We will continue to monitor for developments relating to the Reporting Rule, including developments related to these cases, and whether the Justice Department, the Treasury Department or FinCEN issues any additional guidance to assist clients in navigating BOI Report filing obligations. We will also monitor whether Congress passes any additional legislation to further extend the Reporting Rule deadlines or otherwise modify the CTA.

    Authored by Melissa G.R. Goldstein, Betty Santangelo, Michael S. Didiuk, Jessica Romano, Kyle B. Hendrix and Bryson Kern.

    For assistance in navigating the CTA and Reporting Rule’s reporting requirements, please contact one of the authors or your attorney at Schulte Roth & Zabel.


    [1] For more information, please see our prior Alerts: “Corporate Transparency Act Update: Supreme Court Stays Nationwide Injunction but Reporting Still Voluntary”; “Corporate Transparency Act Update: Preliminary Injunction Reinstated and Reporting Voluntary Once Again”; “Important Update – Corporate Transparency Act: Reporting Reinstated by Appellate Court and FinCEN Extends Deadline to Jan. 13”; “Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary”; and “Corporate Transparency Act Update: Nationwide Preliminary Injunction Enjoining Enforcement”.

    [2] The judge in Smith v. US Department of the Treasury stayed, pending the government’s appeal, his prior Jan. 7, 2025, order that had paused the effective date of the Reporting Rule. In issuing the Feb. 17 order, the judge relied on the US Supreme Court’s order in McHenry v. Texas Top Cop Shop, Inc. that stayed enforcement of a different nationwide preliminary injunction enjoining enforcement of the Reporting Rule.

    [3] FinCEN, “FinCEN Extends Beneficial Ownership Information Reporting Deadline by 30 Days; Announces Intention to Revise Reporting Rule,” FIN-2025-CTA1 (Feb. 18, 2025). Reporting companies that qualify for disaster relief extensions may have extended deadlines that fall beyond March 21, 2025. These companies should abide by whichever deadline falls later.

    [4] See FinCEN, Beneficial Ownership Information, Frequently Asked Questions C.13 and C.14 (last updated July 8, 2024 and Sept. 10, 2024, respectively).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    More insights

  • Corporate Transparency Act Update: Reporting Obligations Reinstated

    Corporate Transparency Act Update: Reporting Obligations Reinstated

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Update: Reporting Obligations Reinstated

    February 19, 2025

    Read time: 4 min

    Key takeaways
    Overview

    What Happened?

    On February 18, 2025, the US District Court for the Eastern District of Texas in Smith v. US Department of the Treasury, No. 6:24-cv-336-JDK, entered an order staying (pausing) the nationwide preliminary injunction against enforcement of the Beneficial Ownership Information Reporting Requirements final rule (31 C.F.R. 1010.380) (Reporting Rule) promulgated under the Corporate Transparency Act (CTA) (31 U.S.C. § 5336).

    Prior to this order, enforcement of the CTA and the Reporting Rule was on hold. On February 18, 2025, in light of this order, the Financial Crimes Enforcement Network (FinCEN) issued a notice that beneficial ownership information (BOI) reporting requirements under the CTA are once again back in effect. View the notice.

    FinCEN extended the deadline 30 calendar days from February 19, 2025, for most reporting companies to file BOI reports. FinCEN also intends to assess its options to further modify reporting deadlines under the Reporting Rule and to initiate a process this year to revise the Reporting Rule to reduce burdens for lower-risk entities, including many US small businesses.

    In depth

    What Now?

    The new deadline for a reporting company to file an initial, updated, and/or corrected BOI report is March 21, 2025. This means:

    1. Non-exempt reporting companies formed on or before February 19, 2025 (including entities formed before the CTA went into effect in 2024), will have until March 21, 2025, to file their BOI reports.
    2. Non-exempt reporting companies formed after February 19, 2025, will have 30 days from their formation/registration to file their BOI reports (unless they otherwise qualify for a later deadline, e.g., disaster relief extension).

    However, FinCEN may issue additional reporting deadline extensions or other guidance relating to BOI reporting, so companies should be prepared to respond to those updates.

    Reporting companies can report their beneficial ownership information directly to FinCEN using FinCEN’s E-Filing system. Get more information.

    McDermott will continue to monitor relevant developments. If you have any questions or need advice on the CTA or its application to your business, please contact your regular McDermott lawyer or one of the authors of this client alert.

    Authors

    Nathan E. Barnett

    Partner

    Wilmington

    Daniel J. Bell

    Partner

    Washington, DC

    More insights

  • New Regime for Management Packages

    New Regime for Management Packages

    ARTICLE / CLIENT ALERT

    New Regime for Management Packages

    February 24, 2025

    Read time: 12 min

    Key takeaways
    Overview

    Article 93 of the 2025 Finance Act of the French Finance Act introduces a tax and social security regime applicable to gains acquired as consideration for duties as a director or employee from 15 February 2025. The tax authorities are awaiting clarification of the practical details of its application.

    Read the full client alert, “Nouveau régime pour les manpacks,” in French.

    In depth

    Régime fiscal et social des management packages issu de la jurisprudence

    Les management packages permettent aux fonds d’investissement de private equity d’associer les managers des sociétés en portefeuille à la réussite des opérations. Ces management packages revêtent en pratique la forme d’une souscription ou acquisition, par les managers, de titres de la société qui les emploie ou de la holding du groupe au sein duquel ils sont employés (actions, obligations, actions gratuites, stock-options ou BSPCE), dont la performance financière dépend de celle de la société émettrice.

    La question du lien entre le management package et les fonctions exercées par les managers qui en bénéficient a alimenté depuis une vingtaine d’années un contentieux avec l’administration fiscale et les URSSAF, qui voient dans ce lien le fondement d’une requalification des gains de cession en salaires.

    En matière fiscale, le Conseil d’État a, par trois décisions du 13 juillet 2021[1], posé le principe selon lequel le gain de cession de titres souscrits ou acquis dans le cadre d’un management package est constitutif d’un salaire (soumis au barème progressif de l’impôt sur le revenu) et non d’une plus-value dès lors qu’il « trouve essentiellement sa source dans l’exercice par l’intéressé de ses fonctions de dirigeant ou salarié ». Le Conseil d’État considère que l’existence d’un tel lien avec les fonctions exercées est établie sur la base d’un faisceau d’indices (notamment l’existence d’un pacte d’actionnaires prévoyant les modalités d’exercice de ses fonctions par le manager, l’incessibilité temporaire des titres qu’il détient, ou une promesse de vente de ses titres en cas de départ, dite promesse leaver), qui ne tient pas compte de l’investissement réalisé ni du risque financier pris par le manager concerné.

    En matière sociale, la Cour de cassation retient une approche comparable à celle du Conseil d’État, en jugeant que le gain de cession est constitutif d’un salaire entrant dans l’assiette des cotisations sociales (salariales et patronales) lorsqu’il est issu de titres proposés aux salariés ou dirigeants en contrepartie ou à l’occasion de leurs fonctions et acquis à des conditions préférentielles[2].

    Au regard de la jurisprudence et de l’interprétation qu’en font l’administration fiscale et les URSSAF, le régime des management packages était une source d’insécurité juridique préjudiciable aux opérations de private equity. L’article 25 bis de la loi de finances pour 2025 vise donc à « clarifier le droit applicable en matière de plans d’investissement des dirigeants et salariés » en prévoyant un régime légal inspiré de la jurisprudence qui leur est propre.

    Régime légal issu de la loi de finances pour 2025

    L’article 25 bis institue un régime fiscal et social applicable aux cessions de titres souscrits ou acquis par des dirigeants ou des salariés, lorsque le gain est acquis en contrepartie de leurs fonctions dans la société émettrice de ces titres ou dans toute société liée, directement ou indirectement, à la société émettrice (le « Gain qualifié »).

    Ce régime s’applique aux cessions de titres réalisées à compter du lendemain de la promulgation de la loi de finances pour 2025, soit le 15 février 2025.

    Régime fiscal

    L’article 156 bis H du code général des impôts (CGI) pose, comme principe général, l’imposition du Gain qualifié selon les règles de droit commun des traitements et salaires (au barème progressif de l’impôt sur le revenu) au titre de l’année au cours de laquelle le bénéficiaire[3] a disposé de ses titres ou les a cédés, convertis ou mis en location.

    Par exception, la fraction du Gain qualifié n’excédant pas trois fois le multiple de performance financière de la société (ou « Multiple projet »), sur la période de détention des titres par le dirigeant ou salarié concerné, bénéficie sous certaines conditions du régime des plus-values de cession de valeurs mobilières.

    Ce Multiple projet correspond au ratio existant entre (i) la valeur réelle de la société émettrice à la date de cession des titres ou de toute autre opération d’échange mentionnée à l’article 150-0 B du CGI (apport, fusion, scission, conversion, etc.) et (ii) la valeur réelle de la société émettrice à la date de souscription ou d’acquisition des titres par le dirigeant ou salarié concerné. Le texte définit la valeur réelle de la société émettrice comme la valeur réelle de ses capitaux propres augmentée de ses dettes envers tout actionnaire ou entreprise liée au sens de l’article 39, 12 du CGI (c’est-à-dire une entreprise contrôlante ou sous contrôle commun avec la société émettrice), étant précisé que la prise en compte de ces dettes dans les capitaux propres ne peut avoir pour effet de relever la limite d’imposition selon le régime des plus-values. Lorsque les titres sont détenus au travers d’une ou plusieurs sociétés regroupant les managers (Manco), la valeur réelle retenue est celle de la société dont les titres sont détenus par ces sociétés.

    Pour bénéficier de cette exception, les titres doivent :

    • présenter un risque de perte en capital ou, pour les titres issus de régimes légaux d’actionnariat salarié (actions gratuites, actions issues de l’exercice de stock-options ou de BSPCE) de perte de la valeur d’acquisition ; et
    • être détenus depuis au moins deux ans, sauf pour les titres issus de régimes légaux d’actionnariat salarié.

    Pour les besoins de la détermination de la fraction du Gain qualifié faisant l’objet d’une imposition au régime des plus-values de cession de valeurs mobilières, les gains d’acquisition d’actions gratuites et les gains d’exercice de stock-options ou de BSPCE seront soustraits du Gain qualifié, de sorte que ces gains continueront à être imposés aux régimes légaux qui les concernent.

    Dans l’hypothèse où les titres seraient souscrits ou acquis à une valeur inférieure à leur valeur réelle, la différence sera également soustraite du Gain qualifié afin d’être imposée au régime des traitements et salaires.

    Par ailleurs, l’article L. 221-31 du code monétaire et financier a été modifié afin d’interdire l’inscription dans un plan d’épargne en actions (PEA) des titres souscrits ou acquis par les dirigeants et salariés en contrepartie de leurs fonctions à compter de la promulgation de la loi. S’agissant des titres qui figureraient déjà sur un PEA, l’article 157, 5° bis du CGI tel qu’amendé par la loi exclut la part du Gain qualifié soumise au régime des traitements et salaires de l’exonération d’impôt sur le revenu dont bénéficient les produits réalisés dans le cadre d’un PEA. Cette disposition sera applicable aux dispositions, cessions, conversions ou mises en location réalisées à compter du 15 février 2025.

    En cas de donation par les dirigeants ou salariés des titres qu’ils ont acquis en contrepartie de leurs fonctions, la part du Gain qualifié soumise au régime des traitements et salaires est déterminée et imposée au nom du donateur au titre de l’année au cours de laquelle le donataire a disposé de ses titres ou les a cédés, convertis ou mis en location.

    En cas d’apport des titres ou de fusion-absorption de la société émettrice des titres en question, la part du Gain qualifié soumise au régime des traitements et salaires n’est pas éligible aux sursis et report d’imposition prévus par les articles 150-0 B et 150-0 B ter du CGI, celui-ci devenant donc imposable au jour de la réalisation de l’opération.

    Régime social

    En vertu des articles L. 136-1-1, III, 3° a bis et L. 242-1, II, 8° du code de la sécurité sociale (CSS), le Gain qualifié, qu’il soit imposé selon le régime des traitements et salaires ou celui des plus-values de cession de valeurs mobilières, est exclu de l’assiette de la contribution sociale sur les revenus d’activité et sur les revenus de remplacement et de l’assiette des cotisations de sécurité sociale dues par l’employeur.

    L’article L. 137-42 du CSS prévoit que la fraction du Gain qualifié soumise au régime des traitements et salaires est exonérée de prélèvements sociaux (y compris de la CSG et CRDS sur les salaires) mais assujettie à une nouvelle contribution salariale libératoire de 10% due par les bénéficiaires. Compte tenu de la progressivité du taux de l’impôt sur le revenu, son imposition pourrait donc atteindre le taux marginal de 59% (par comparaison au taux de 34% pour les plus-values), en ce compris la contribution exceptionnelle sur les hauts revenus.

    Conformément à l’article L. 136-6, I, e du CSS, la fraction du Gain qualifié soumise au régime des plus-values de cession de valeurs mobilières reste passible des prélèvements sociaux sur les revenus du patrimoine au taux global de 17,2%.

    Le régime social s’applique aux dispositions, cessions, conversions ou mises en location réalisées entre le 15 février 2025 et le 31 décembre 2027, et n’est donc que temporaire.

    Questions soulevées par ce régime légal

    Si l’on peut regretter que le texte consacre l’application du régime des traitements et salaires comme principe et l’application du régime des plus-values de cessions de valeurs mobilières comme exception (à rebours de la jurisprudence), il permet de sécuriser le traitement fiscal et social des gains issus de management package.

    Pour autant, le nouveau régime, qui n’a pas été débattu au Parlement, ne va pas sans soulever un certain nombre de questions et laisse un large champ d’interprétation à l’administration fiscale.

    Tout d’abord, le texte ne précise pas ce qu’il convient concrètement d’entendre par gain « acquis en contrepartie des fonctions de salarié ou de dirigeant », ce qui est pourtant un point essentiel du dispositif, même si l’on peut subodorer que l’administration fiscale et les URSSAF interpréteront cette condition à la lumière de la jurisprudence précitée, elle-même source d’incertitudes.

    Compte tenu de sa rédaction, on peut se demander si le nouveau texte ne pourrait pas viser tous les titres détenus par les managers (en ce compris les titres pari passu détenus également par d’autres investisseurs que les managers), et pas seulement ceux réservés aux managers (telles que les ADP ratchet), dès lors que les titres dont il s’agit font l’objet d’une promesse leaver. Pour autant, le texte ne devrait pas concerner les titres détenus par les fondateurs. L’application du régime s’effectuant sur une base déclarative, les praticiens devront veiller à ce que les déclarations des différents managers participant à la même opération soient cohérentes.

    Par ailleurs, lorsque les titres ont été souscrits ou acquis à des dates différentes, le texte prévoit que le Gain qualifié et le Multiple projet doivent être calculés distinctement à chacune de ces dates (ce qui donnera lieu à certaines difficultés pratiques, notamment pour les actions gratuites qui sont émises par tranches). En outre, rien dans le texte ne permet d’assurer que le Gain qualifié puisse être apprécié globalement pour l’ensemble des catégories de titres souscrits ou acquis par un même manager, de sorte que le multiple réalisé puisse être lissé. Si les commentaires administratifs attendus sur ce texte ne validaient pas cette approche globale, la mise en œuvre du régime légal pourrait s’avérer très pénalisante pour les opérations en cours, et conduirait les praticiens à recommander pour les opérations futures le regroupement des différents droits financiers alloués aux managers dans un instrument unique.

    S’agissant des PEA, le texte condamne définitivement leur usage dans les opérations de private equity, ce qui soulève une difficulté pratique pour les managers qui détiennent actuellement leurs titres en PEA et seront amenés à réinvestir dans les opérations futures car ils ne pourront procéder à l’apport de leurs titres, sauf à considérer que les nouveaux titres ne sont pas concernés par le régime. En outre, la question se pose de savoir si les managers qui perdront le bénéfice de l’exonération d’impôt sur le revenu sur la fraction du Gain qualifié soumise au régime des traitements et salaires pourront retirer les sommes concernées sans supporter les prélèvements sociaux. Des précisions sont également attendues sur le sort des retraits effectués sur les PEA ouverts depuis moins de cinq ans, qui devraient, logiquement entraîner la perte de l’exonération d’impôt au titre de l’ensemble des avoirs du PEA concerné.

    Enfin, le texte n’a pas d’effet rétroactif et ne s’applique pas aux gains réalisés antérieurement au 15 février 2025. Pour autant, il nous semble que l’administration fiscale pourrait s’en inspirer dans le cadre de certains litiges portant sur les management packages débouclés avant cette date (notamment ceux qui ne sont pas structurés uniquement avec des instruments ratchet), afin d’en faciliter la résolution dans un cadre apaisé.

    Authors
    More insights

  • FDA Relaxes Critical Positions on Use of Scientific Information in Off-Label Communications

    FDA Relaxes Critical Positions on Use of Scientific Information in Off-Label Communications

    ARTICLE / CLIENT ALERT

    FDA Relaxes Critical Positions on Use of Scientific Information in Off-Label Communications

    February 18, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On January 6, 2025, the US Food and Drug Administration (FDA) published final guidance titled “Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers.”

    The guidance finalizes FDA’s revised draft guidance issued in October 2023 concerning firm-initiated communications of scientific information on unapproved uses (SIUU) of approved or cleared medical products to healthcare providers (HCPs) who prescribe for, or administer medical products to, patients. Broadly, the final guidance steps back from FDA’s position in the draft guidance that appeared to afford FDA greater discretion for determining communications to be inappropriate. This increased discretion would have heightened regulatory risk, and industry stakeholders widely criticized the stance. The comparatively modest approach of the final guidance emphasizes that any communication regarding unapproved uses must be truthful, comprehensive, and focused on the scientific content rather than promotional tactics, which do not align with the intent of informing clinical practice.

    In depth

    Background

    The Federal Food, Drug, and Cosmetic Act and the Public Health Service Act prohibit the introduction of medical products into interstate commerce if they do not comply with premarket requirements or are misbranded or adulterated. This prohibition includes distributing medical products for unapproved uses, even if the product is approved for other purposes. HCPs often seek SIUU to enhance their clinical practice. However, a firm’s communication about SIUU can indicate improper intent, potentially violating federal law.

    The FDA’s final guidance defines “firms” as entities responsible for labeling medical products, including manufacturers, distributors, and their representatives. The guidance outlines the characteristics of source publications in firm-initiated communications that fall within the enforcement policy and provides recommendations for sharing published scientific articles, clinical practice guidelines, reference texts, and digital clinical practice resources. Firm-generated presentations of SIUU, when provided with a source publication, are subject to different considerations than those consisting solely of source publications and recommended disclosures. These source publications should come from independent publishers with editorial input to ensure they are not influenced by the firm’s business interests.

    Updates to Guidance

    Source Publication Considerations

    FDA makes a noteworthy change in the final guidance by not preserving the 2023 drafted standard that source publications should provide “clinically relevant” information. Industry members submitted comments that this element of the SIUU analysis was too subjective and challenging to implement. Instead, FDA preserves only a “scientifically sound” standard that will likely give companies more flexibility in how they can align with FDA’s recommendations. Accordingly, FDA recommends the following:

    • Source publications that firms include in SIUU communications should detail studies and analyses that are scientifically sound.
    • Firms should take into account existing scientific knowledge to determine whether a source publication is appropriate to include in an SIUU communication.
    • Any conclusions articulated in a source publication should align with the prespecified hypothesis or research question from the described study or analysis and be supported by the results from that study or analysis.

    With the removal of the “clinically relevant” standard, FDA has assuaged industry frustration over the previous language that would have limited the use of “early-stage” clinical data (including Phase II) and recommended against the use of certain studies, including those without an adequate comparison or control group. These forms of data likely wouldn’t have met the drafted “clinically relevant” standard but can be considered scientifically sound under the final guidance.

    Presentational Considerations to Take Into Account

    While FDA allows companies to communicate off-label drug uses, the 2023 draft guidance left the industry feeling vulnerable to prosecution if the agency considered their communications promotional in nature. Therefore, the final guidance clarified that communications that “encourage the unapproved use of the firm’s medical product based on elements other than the communication’s scientific content” do not fall within FDA’s enforcement policy on SIUU communications. SIUU communications should instead:

    • Clearly and prominently present the disclosures recommended in the guidance (e.g., use audio and visual components to help HCPs notice and comprehend the information)
    • Be separate from promotional communications about approved uses of medical products (e.g., use a web page for SIUU communications and a separate web page for promotional communications about the approved uses)
    • Be shared through media and via platforms that enable firms to implement the recommendations in this guidance (e.g., certain online platforms may impose character-space limitations that would not permit a firm to include all of the disclosures recommended).

    These recommendations show a significant shift from the 2023 draft guidance by completely omitting language that suggested SIUU communications “should not use persuasive marketing techniques” and firms should differentiate channels for SIUU communications from promotional activities to reduce any risk. This is a direct result of trade groups and pharmaceutical companies pushing back against the draft guidance and providing comments stating that FDA failed to clearly describe what the agency considers to be “persuasive marketing techniques.” The final guidance’s change in language should certainly prove beneficial to medical product companies.

    Additional Recommendations for Digital Clinical Practice Resources

    Prior to FDA’s 2023 draft guidance, the agency had advised firms not to emphasize portions of scientific articles suggesting the safety or efficacy of off-label uses when disseminating medical publications. Pharmaceutical companies and trade groups were concerned that the draft guidance only allowed firm-created presentations based on article reprints. In the final guidance, FDA clarifies that presentations are no longer restricted to reprints only, but firms can now summarize Clinical Practice Guidelines, reference texts, and materials from digital clinical practice resources that are included in an SIUU communication.

    Recommendations for Firm-Generated Presentations

    Some firms develop firm-generated presentations to include in their SIUU communications, which involve additional considerations since the firms themselves are creating the communications. The final guidance recommends that a firm-generated presentation have all of the following characteristics if a firm chooses to include it in an SIUU communication:

    • Be limited to the SIUU from one or more source publications and be consistent with the other recommendations of this guidance
    • Provide the source publication(s) with the presentation
    • Include all information material to the representations made
    • Clearly disclose what portions of the SIUU communication are firm generated (e.g., “This presentation was developed by FIRM X”).

    These recommendations solidify FDA’s shift toward allowing firms to summarize scientific findings when disseminating medical journal articles to HCPs, which the 2023 draft guidance had newly suggested.

    Additionally, after demands for clarity from industry members, the final guidance provides examples of promotional communication techniques that fall outside of the final guidance’s enforcement policy, which include celebrity endorsements, premium offers, and promotional tag lines.

    Key Takeaways

    • The final guidance appears balanced more towards pharmaceutical companies’ and trade groups’ interests following heavy pushback against the draft version. This final guidance focuses on the industries interests in HCPs receiving SIUU of approved or cleared medical products to inform clinical practice decisions for the care and management of individual patients with the various government interests in incentivizing the development and satisfaction of premarket requirements for medical products.
    • In firm-generated presentations, FDA no longer limits SIUU communications to information from an accompanying reprint. However, using promotional communication techniques to encourage the unapproved use of a firm’s medical product based on elements other than the communication’s scientific content does not appropriately serve the purpose of informing clinical practice decisions for the care and management of individual patients and is therefore excluded from FDA’s enforcement policy on SIUU communications.

    If you have questions about how FDA’s final guidance on SIUU communications could impact your business, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Brigit Dunne

    Associate

    Chicago

    More insights